{"id":"W3087416729","doi":"10.1056/nejmoa2022485","title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":766,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Daiichi Sankyo Europe; Pharmacyclics; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; Sierra Oncology; Bavarian Nordic; Astellas Pharma; Eisai; Celldex Therapeutics; Daiichi-Sankyo; Clovis Oncology; National Institute for Health and Care Research; AstraZeneca; Invitae; Ipsen; Vertex Pharmaceuticals; Boston Scientific Corporation; Endocyte; NRG Oncology; F. Hoffmann-La Roche; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Prostate cancer; Oncology; Medicine; Internal medicine; Cancer research; Cancer; Biology; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004629795,0.0001395638,0.0005330411,0.0001404356,0.00002713943,0.00001011545,0.00007294373,0.00002278436,0.0002925131],"category_scores_gemma":[0.000162484,0.00007176455,0.00003617167,0.000375584,0.00009950253,0.00009909861,0.000009278901,0.0003915358,0.000002315568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009588481,"about_ca_system_score_gemma":0.000906772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004632431,"about_ca_topic_score_gemma":0.000495987,"domain_scores_codex":[0.9984633,0.00007884821,0.0004392337,0.0001334051,0.0006591092,0.0002260954],"domain_scores_gemma":[0.9989265,0.0001103692,0.0001846889,0.00007938533,0.0002258442,0.000473225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1133342,0.0006231216,0.4448446,0.001242507,0.002033114,0.02567574,0.03468267,0.001046484,0.1026893,0.0003385417,0.01812837,0.2553613],"study_design_scores_gemma":[0.6512006,0.03602867,0.1969521,0.004987217,0.001725541,0.001925419,0.006239423,0.0005716835,0.007868824,0.0004887402,0.09146899,0.0005427431],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8891492,0.006396201,0.0001097314,0.1027913,0.0001954304,0.0003924016,0.000008500361,0.00000979884,0.0009473976],"genre_scores_gemma":[0.9955412,0.001462893,0.0004333335,0.0005807184,0.001399819,0.000004834671,0.00001002707,0.00001733471,0.0005498229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5378664,"threshold_uncertainty_score":0.3202814,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06052038105550388,"score_gpt":0.343200598017492,"score_spread":0.2826802169619881,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}